Georgia's Online Cancer Information Center

Leukemia Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Leukemia
Cancer Type = Leukemia
There are currently 26 active Leukemia clinical trials in Georgia.
1.
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Cancer Type
Leukemia
NCT ID
NCT01503632
Protocol IDs
ACCL1033
COG-ACCL1033
CDR0000721559
NCI-2012-00105
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
2.
A Phase 1 / 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Non-Hodgkin's Lymphoma (NHL)
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT03740529
Protocol IDs
LOXO-BTK-18001
NCI-2019-02015
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
4.
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCT ID
NCT02732275
Protocol IDs
DS3201-A-J101
NCI-2019-00366
Treatment Sites (1)
5.
NCORP Trial
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)
NCT ID
NCT02730312
Protocol IDs
XmAb14045-01
NCI-2016-00916
Treatment Sites (4)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma
NCT ID
NCT03236857
Protocol IDs
M13-833
NCI-2017-02027
2017-000439-14
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
8.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCT ID
NCT03420183
Protocol IDs
CIRM-0001
NCI-2018-00270
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Cancer Type
Eye Cancer, Leukemia
NCT ID
NCT03011372
Protocol IDs
INCB 54828-203
NCI-2017-00141
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
13.
A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02396134
Protocol IDs
13494
NCI-2015-00283
118814
121375
119250
118207
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
15.
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia
Cancer Type
Acute Lymphoblastic Leukemia, Leukemia, Lymphoma
NCT ID
NCT02879643
Protocol IDs
T2012-002
NCI-2016-01398
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
16.
17.
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Cancer Type
Leukemia, Lymphoma
NCT ID
NCT03701282
Protocol IDs
EA9161
EA9161
NCI-2018-02127
Treatment Sites (3)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
19.
Assessing Financial Difficulty in Patients with Blood Cancers
Cancer Type
Leukemia
NCT ID
NCT03870633
Protocol IDs
A231602CD
A231602CD
NCI-2018-01708
A231602CD
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
20.
NCORP Trial
Assessing the Impact of a Simplified Patient Care Strategy to Decrease Early Deaths In Acute Promyelocytic Leukemia (APL) By Maintaining A Database
Cancer Type
Leukemia
NCT ID
NCT02309333
Protocol IDs
IRB00067432
WINSHIP2488-13
EA9131
Treatment Sites (2)
21.
NCORP Trial
Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Cancer Type
Leukemia
NCT ID
NCT01688011
Protocol IDs
Connect® MDS/AML Registry
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
22.
23.
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients with Lymphoma
Cancer Type
Leukemia
NCT ID
NCT03501576
Protocol IDs
Winship4236-17
NCI-2017-02313
IRB00101067
Treatment Sites (2)
24.
GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Cancer Type
Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03320642
Protocol IDs
INCB 39110-119/GRAVITAS-119
NCI-2018-00119
Treatment Sites (1)
25.
Matched Targeted Therapy (MTT) Recommendation for Patients with Recurrent, Refractory, or High Risk Leukemias
Cancer Type
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02670525
Protocol IDs
15-384
NCI-2016-00336
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.